Company intelligence / Profile preview

Heilongjiang Longwei Precision Medicine Laboratory

Harbin, Heilongjiang, China

Ownership: Private
Development stage: Other

Overview

The laboratory is conducting a large-scale colorectal cancer risk assessment initiative for approximately 800,000 eligible individuals aged 45-64 using gene methylation technology for early detection and preventive care

Therapeutic areas: Oncology
Industry: Molecular Diagnostics

Partnerships

BGI Genomics (Strategic partnership for BGI-HL OHA Intelligent Laboratory)

Beyond the preview

Go deeper on Heilongjiang Longwei Precision Medicine Laboratory.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heilongjiang Longwei Precision Medicine Laboratory.

Explore the full profile